Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Summary

All patients who participate in this study will receive pazopanib. Pazopanib is an oral drug (pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer. In this study, the investigators plan to learn more about the way this drug works by using special scans (MRIs and Ultrasounds) to help evaluate how this drug is working on this disease. Approximately 20 people with advanced kidney cancer will be enrolled on this study.

Timeline

Start

2010-10

Primary completion

2015-06

Completion

2019-04

Drugs

Indications